<DOC>
	<DOC>NCT00640549</DOC>
	<brief_summary>The study will investigate the effects of atorvastatin on the concentrations of small, dense LDL and HDL subfractions in patients with diabetes and the underlying mechanisms of these effects.</brief_summary>
	<brief_title>Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus</brief_title>
	<detailed_description>This study was terminated on October 6, 2004. The study terminated prematurely because of a higher screening failure rate than expected. There were no safety or efficacy reasons involved in the decision to terminate.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Male and female subjects with a diagnosis of type 2 diabetes mellitus who either have never had a major adverse cardiac event (MACE) diagnosed before or who had a MACE diagnosed at least 6 months ago, but who, according to the judgement of the treating general practitioner, do not receive any hyperlipidemic therapy. Major adverse cardiac events (MACE) include myocardial infarction, coronary angioplasty, coronary artery bypass graft or other revascularization procedures. At Screening: Visit 1 (week 4): 1. Male patients aged &gt;35 and ≤75 years and postmenopausal female patients ≤75 years with a diagnosis of type 2 diabetes mellitus 2. Patients have been euthyroid for at least six months 3. Written informed consent obtained At Visit 2 (week 0): 4. LDL cholesterol ≥130 mg/dl (3.3 mmol/l ) and &lt;190 mg/dl (4.9 mmol/l) 5. Triglycerides &lt;150 mg/dl (1.69 mmol/l ) and &lt;600 mg/dl (11.3 mmol/l) 6. Sum of LDL5 and LDL6 cholesterol ≥25 mg/dl (0.65 mmol/l) 7. Follicle stimulating Hormone (FSH) &gt;30 U/l in female patients aged &lt;60 years or FSH &gt;20 U/l in female patients aged ≥60 years HbA1c &gt; 8.0 Creatine kinase (CK) &gt;5 times the upper limit of normal Patients having taken lipid lowering medication within 8 weeks of the screening visit</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>LDL-subfractions, HDL-subfractions, non insulin dependent diabetes mellitus (NIDDM), hyperlipidemia, atorvastatin</keyword>
</DOC>